Differential Regulation of Tau Exon 2 and 10 Isoforms in Huntington’s Disease Brain

• Published in: Neuroscience Vol. 518; pp. 54 - 63
• Main Authors: Petry, Serena, Nateghi, Behnaz, Keraudren, Rémi, Sergeant, Nicolas, Planel, Emmanuel, Hébert, Sébastien S., St-Amour, Isabelle
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 10.05.2023
• Subjects: Alternative Splicing; Brain - metabolism; Cortex; Exons; Humans; Huntingtin Protein - genetics; Huntington Disease - pathology; Huntington’s disease; Neurodegeneration; Protein Isoforms - genetics; Protein Isoforms - metabolism; Putamen; Splicing; Tau; tau Proteins - genetics; tau Proteins - metabolism; Splicing; Darpp-32; Cortex; Tau; NIH; Putamen; GFAP; NeuN; Neurodegeneration; Huntington’s disease; HD; PSD-95; PCR; SNAP-25; BA
• ISSN: 0306-4522; 1873-7544; 1873-7544
• DOI: 10.1016/j.neuroscience.2022.07.014

•Huntington’s disease is associated with deficits in MAPT alternative splicing.•Higher tau exon 10 inclusion is a common trait of HD and consistently observed in both cortex and putamen.•Lower tau exon 2 inclusion is specific to one region analyzed, the putamen, precedes tau hyperphosphorylation, and coincides with neurodegeneration.•Our findings suggest isoform-specific functions of tau in HD neuropathology. Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by an expansion of CAG repeats in the Huntingtin (HTT) gene. Accumulating evidence suggests that the microtubule-associated tau protein participates in the pathogenesis of HD. Recently, we have identified changes in tau alternative splicing of exons 2, 3 and 10 in the putamen of HD patients (St-Amour et al, 2018). In this study, we sought to determine whether tau mis-splicing events were equally observed in other brain regions that are less prone to neurodegeneration. Using Western blot and PCR, we characterized the relationship between MAPT splicing of exons 2, 3 and 10, tauopathy and Htt pathologies, as well as neurodegeneration markers in matching putamen and cortical samples from HD (N = 48) and healthy control (N = 25) subjects. We first show that levels of 4R-tau (exon 10 inclusion) isoforms are higher in both the putamen and the cortex of individuals with HD, consistent with earlier findings. On the other hand, higher 0N-tau (exclusion of exons 2 and 3) and lower 1N-tau (exclusion of exon 3) isoforms were seen exclusively in the putamen of HD individuals. Interestingly, investigated splicing factors were deregulated in both regions whereas exon 2 differences coincided with increased tau hyperphosphorylation, aggregation and markers of neurodegeneration. Overall, these results imply a differential regulation of tau exon 2 and exon 10 alternative splicing in HD putamen that could provide a useful biomarker or therapeutic target.